During the past decade, RED-Institut GmbH conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 6 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 6 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "RED-Institut GmbH" are "Type 2 Diabetes" (7 trials), "Type 1 Diabetes Mellitus" (3 trials), "Crohn's Disease" (2 trials), "Type 2 Diabetes Mellitus" (2 trials) and "Diabetes" (1 trials). Many other conditions were trialed in "RED-Institut GmbH" in a lesser frequency.

Most popular intervention types in "RED-Institut GmbH" are "Drug" (15 trials). Other intervention types were less common.

The name of intervention was led by "Tirzepatide" (6 trials), "Insulin Degludec" (4 trials), "Placebo" (4 trials), "Dulaglutide" (3 trials) and "Insulin Efsitora Alfa" (2 trials). Other intervention names were less common.

The vast majority of trials in "RED-Institut GmbH" are 15 trials for "All" genders.

Currently, there are NaN active trials in "RED-Institut GmbH". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in RED-Institut GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in RED-Institut GmbH, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".